 | | | | Related Healthscout Videos | |
|
Page: << Prev | 1 | 2 "One potential benefit of the new CGRP receptor antagonist class of acute migraine treatments is the absence of vasoconstriction, a liability of the triptans, which may allow for the safe administration of telcagepant in patients with migraine with cardiovascular disease," the study authors wrote. "However, such patients were excluded from the present study because of the contraindication for zolmitriptan, and further studies are necessary to determine the safety of telcagepant in patients with cardiovascular disease. Additional studies are also necessary to assess the long-term efficacy and safety profile of telcagepant in patients treating more than one migraine attack."
The study was published online Nov. 25 and in an upcoming print issue of The Lancet. Preliminary results from the trial were presented in June at the American Headache Society's annual meeting, in Boston.
"This result marks a new era in migraine therapy. However, the remaining issue is to understand the site of action of the CGRP-receptor antagonists," Dr. Lars Edvinsson, of Lund University in Sweden, wrote in an editorial comment accompanying The Lancet study.
Text Continues Below
More information
The American Academy of Neurology has more about migraine treatments.
Page: << Prev | 1 | 2
-- Robert Preidt
|
.gif)
